entertainment -WSS

entertainment

author：entertainment 2025-08-11 07:58:48 - browse：1

A DNA helix, with dollar banknotes covering its strands, collapses next to another DNA helix with dollar banknotes strands — coverage from STAT — Adobe

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new form of genome editing.

Prime and Myeloid Therapeutics, a startup co-founded by Pulitzer Prize-winning writer and cancer biologist Siddhartha Mukherjee, have filed competing arbitration claims over a deal they signed in March 2022.

Prime, spun out of the lab of Broad Institute biochemist David Liu, was built on technology for making small insertions, deletions, and single-letter changes in DNA. In theory, prime editing allows researchers to tackle the vast majority of disease-causing mutations, and the first treatments are already being readied for clinical trials. But it’s a poor fit in cases where hundreds or even thousands of different mutations in a long gene cause the same diseases, such as cystic fibrosis or Duchenne muscular dystrophy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Food makers to regulators: Ultra

explore

WSS

Experimental asthma app from Apple and Anthem shows promise

New weight loss drugs vying to be the next Wegovy or Mounjaro

Food makers tried to stack nutrition panel with preferred experts

NIH chief: government has fallen behind pharma on clinical trials

Weight loss drugs should be covered by insurers, AMA says

IRA could hurt research into orphan drugs for rare diseases

knowledge

entertainment

hotspot

The high cost of giving birth even with insurance

Diverse clinical trials: Why aren’t we there yet?

Continuity nursing helped my family in our darkest PICU moments

How medical schools plan to diversify without affirmative action

Walensky prepares to leave CDC — and Congress — behind

Generate Biomedicines machine learning biotech raises $273M

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Walensky prepares to leave CDC — and Congress — behind

White House touts steps to stem shortages of cancer treatments

hotspot

Weight loss drugs should be covered by insurers, AMA says

How to make the FDA’s new prescription one

Ventyx halts psoriasis drug development after lackluster trial results

Cancer diagnosis changes perspective doctor, former hospital CEO

Medicare’s new pay boost for primary care is angering specialists

Long Covid needs a new name — and a new frame

entertainment

focus

explore

entertainment